Allarity Therapeutics has received notice from Nasdaq granting them a hearing before a Nasdaq Hearings Panel, scheduled to take place in approximately 5 weeks. The hearing will allow the company to present its plan for regaining compliance following notification of non-compliance with the Bid-Price Rule, which requires maintaining a minimum bid price of $1.00 per share for at least 30 consecutive business days.The company formally submitted its hearing request on June 25, 2024, following the non-compliance notification disclosed on June 21, 2024. Allarity has already begun preparing for the hearing and has implemented a preparation schedule to ensure thorough readiness. The company is currently focused on the development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, in an ongoing phase 2 clinical trial.

Allarity Therapeutics has received notice from Nasdaq granting them a hearing before a Nasdaq Hearings Panel, scheduled to take place in approximately 5 weeks. The hearing will allow the company to present its plan for regaining compliance following notification of non-compliance with the Bid-Price Rule, which requires maintaining a minimum bid price of $1.00 per share for at least 30 consecutive business days.The company formally submitted its hearing request on June 25, 2024, following the non-compliance notification disclosed on June 21, 2024. Allarity has already begun preparing for the hearing and has implemented a preparation schedule to ensure thorough readiness. The company is currently focused on the development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, in an ongoing phase 2 clinical trial.